Menu
Recruiting NCT06051773

Evaluation of Muscle Involvement in Systemic Sclerosis

Observational Systemic Sclerosis

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: muscle involvement.
Who it may be relevant to
Registry conditions: Systemic Sclerosis. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

Muscle involvement is poorly described in patients with systemic sclerosis (SSc) . The prevalence of muscle damage is evaluated at 5-95 % of SSc patients, particularly due to variable definitions depending on the series in the scientific litterature. Muscle clinicobiological and histological presentation an response to immunosuppressive treatments are highly variable. Muscle involvement defined by creatinine kinase (CK) elevation, the presence of electromyography (EMG) abnormalities and/or muscle magnetic resonance imaging (MRI) hyperintensities and/or muscle biopsy inflammation appears to be associated with diffuse SSc, the presence of cardiac damage, and anti-PM-Scl antibodies. The main objective is to describe muscular manifestations associated with SSc. Secondary objectives are: * to compare characteristics between SSc patients with and without muscle involvement * to determine homogeneous groups of SSc patients with muscle involvement

Interventions

  • Other muscle involvement
    evaluation of muscle involvement

Primary outcome measures

  • Number of patients with muscle involvement [Time frame: baseline (J0)]

Eligibility criteria

Inclusion criteria

  • Patients with systemic sclerosis according to 2013 ACR/EULAR classification criteria

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

France · 1 center
  • Paul Decker — Nancy

Identifiers

NCT: NCT06051773 · 2023PI160

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗